SWOG clinical trial number
S9712

Phase II Trial of Concurrent Carboplatin/VP-16 and Radiation Followed by Paclitaxel (Taxol®) For Poor-Risk Stage III Non-Small Cell Lung Cancer

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Stage III NSCLC
Activated
02/15/1998
Closed
06/01/2000
Participants
NCORP, Members

Research committees

Lung Cancer

Publication Information Expand/Collapse

2019

Clinical prognostic model for older patients with advanced non-small cell lung cancer

AK Ganti;X Wang;T Stinchcombe;Y Wang;J Bradley;HJ Cohen;K Kelly;R Paulus;SS Ramalingam;EE Vokes;H Pang Journal of Geriatric Oncology Feb 20. pii: S1879-4068(18)30197-8. doi: 10.1016/j.jgo.2019.02.007. [Epub ahead of print]

PMid: PMID30797707

2016

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials

D Hershman;C Till;J Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology Sep 1;34(25):3014-3022; 2016 Jun 20 [Epub ahead of print]

PMid: PMID27325863 | PMC number: PMC5012713

Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials

DL Hershman;C Till;JD Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology 34, 2016 (suppl; abstr 10001); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation

2006

Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712

AM Davies;K Chansky;DHM Lau;BR Leigh;LE Gaspar;GR Weiss;AJ Wozniak;JJ Crowley;DR Gandara Journal of Clinical Oncology 24(33):5242-5246

2002

Concurrent carboplatin/etoposide and radiation followed by paclitaxel consolidation for poor risk stage III non-small cell lung cancer: a Southwest Oncology Group (SWOG) phase II trial (S9712)

A Davies;D Lau;J Crowley;B Leigh;DR Gandara Proc of the American Society of Clinical Oncology 21:298a(#1191)

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase